Jeffrey Bradley named interim chair of Emory Department of Radiation Oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jeffrey Bradley was named interim chairman of the Emory University Department of Radiation Oncology.

Bradley, previously the executive vice chairman of the department, succeeds former Winship Cancer Institute Executive Director Walter J. Curran, Jr., who announced in October 2020 that he would be stepping down from his role as chair (The Cancer Letter, Jan 22, 2021).

Bradley joined Winship in 2019 from Washington University School of Medicine in St. Louis where he was the S. Lee Kling Endowed Professor of Radiation Oncology and clinical director of the Kling Proton Center.

Bradley led the effort to open the world’s first single-room proton center at Washington University’s Barnes-Jewish Hospital. He is a founding member of the Particle Therapy Oncology Group of North America and the chairman of the NRG Oncology Lung Cancer Committee.

Since joining Winship, Bradley has been appointed the James W. Keller, MD Distinguished Professorship in Radiation Oncology in support of his research in innovative radiation therapy technologies such as proton beam therapy and stereotactic body radiation therapy.

Curran was chairman of the Department of Radiation Oncology for 13 years. He led efforts to open the Emory Proton Therapy Center, exclusively operated by department faculty and staff, which treated over 400 patients in its first year, and expanded basic, translational, and clinical research during his tenure.

In mid-January, the Department of Radiation Oncology appointed Curran as professor emeritus.

Table of Contents

YOU MAY BE INTERESTED IN

Just consider for a minute if this was the first year of running your lab, if you were on the job market as a physician or scientist right now, if you were a resident contemplating a career in cancer research after fellowship, if you were a graduate student or postdoc, if you were an undergraduate or a technician who was looking toward graduate school.
The immune system can be a powerful tool to control cancer. Immune cells within our body detect cancer cells and release payloads that kill them. Transformative science in the last decade has led to the development of therapies that enhance the ability of our immune cells to carry out this function. These therapies, including checkpoint blockade and CAR-T cells, have been lifesaving for many patients that before had untreatable cancer. But, sadly, a majority of patients with advanced solid tumors still succumb to their disease. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login